Clinical trials: Scleroderma
Systemic Sclerosis-Associated PAH
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious, life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the connective tissue characterized by scarring (fibrosis)…
- Trial name
- NCT01086540
- Testing
- Rituximab, CMRI, prednisone
- Where
- 17 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Scleroderma, Systemic
Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma
The purpose of this study is to develop an evidence-based educational program for scleroderma patients with hand dysfunction. The program includes a self-care handbook and multimedia video resources.
- Trial name
- NCT06697561
- Testing
- patient education program
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Wen-Shao Lin
Scleroderma, Systemic, Graft Vs Host Disease
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
Extracorporeal photopheresis (ECP), also known as extracorporeal photoimmunotherapy or photochemotherapy, is a leukapheresis-based therapy that has been in clinical use for over three decades after receiving FDA approval in 1988.
- Conditions
- Scleroderma, Systemic, Graft Vs Host Disease, Eosinophilic Fasciitis, Morphea
- Trial name
- NCT04752397
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Charite University, Berlin, Germany
Systemic Sclerosis
Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis
Relma-cel is a product containing CD19-CAR-transduced T cells. The purpose of this study is to evaluate the safety of Relma-cel at different dose levels in patients with early diffuse systemic sclerosis.
- Trial name
- NCT06414135
- Testing
- Relma-cel
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Liangjing Lu
Active Digital Ulcers
Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis
This is a pilot study analyzing the effect of sildenafil therapy on digital ulcers in systemic sclerosis. We want to analyze ulcer healing by measuring the size of digital ulcers and their count and analyze the effect of…
- Trial name
- Sildenafil (NCT00624273)
- Testing
- Sildenafil therapy
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Charite University, Berlin, Germany
Systemic Lupus Erythematosus, Systemic Sclerosis
Neutrophil Extracellular Traps in Systemic Sclerosis
Systemic sclerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Trial name
- NET-SSC (NCT03374618)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Connective Tissue Diseases, Blood Coagulation Disorders
CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study
To explore the hypothesis that leg ulcers are associated with hypercoagulable states, the CLUE study will evaluate patients with connective tissue disease associated leg ulcers, to identify risk factors (especially…
- Conditions
- Connective Tissue Diseases, Blood Coagulation Disorders, Leg Ulcers, Rheumatoid Arthritis
- Trial name
- CLUE (NCT00522002)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- George Washington University
Rheumatic Diseases, Rheumatoid Arthritis (RA)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases.
- Conditions
- Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA)
- Trial name
- CARe RAiSE (NCT07150000)
- Testing
- Ex Vivo Assay
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Scleroderma, Calcinosis Cutis
Effectiveness of ESWT and PNF in Scleroderma With Calcinosis
Investigation of the effects of ESWT and PNF exercises added to ESWT on calcinosis in Ssc patients. Calcinosis cutis is a common, difficult-to-treat manifestation of systemic sclerosis associated with high morbidity.
- Trial name
- NCT05870852
- Testing
- Extracorporeal Shock Wave Therapy (ESWT), PNF
- Volunteers
- 30 people
- Sponsor
- Istanbul University
Systemic Sclerosis
Ultrasound Therapy and Manual Therapy in Digital Ischemic Ulcers
The objective of this before-after non-randomized trial study is to evaluate the efficacy of ultrasound therapy in combination with manual therapy in the management of systemic sclerosis patients with IDU.
- Trial name
- NCT05907200
- Testing
- combination ultrasound therapy and manual therapy, manual therapy
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Palermo
Severe Systemic Sclerosis
Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, severe and chronic systemic autoimmune disease (AD) characterized by vasculopathy, immune dysregulation and fibrosis leading to multi-organ dysfunction (primarily skin, lungs, heart…
- Trial name
- MSC-AT-SSc (NCT06722105)
- Testing
- 2 infusions of MSC, 1 infusion of MSC
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Diffuse Cutaneous Systemic Sclerosis
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Trial name
- NCT07287670
- Testing
- MTX-474
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 85 people
- Sponsor
- Mediar Therapeutics
Systemic Sclerosis
Professional and Personal Toxic Exposure in Systemic Sclerosis : Type, Intensity and Probability of Exposition
Systemic Sclerosis (SSc) is an inflammatory chronic disease that can lead to structural damage and handicap. The SSc physiopathology is multifactorial, including genetic and environmental risk factors.
- Trial name
- VISSEXPOSITION (NCT03543956)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 226 people
- Sponsor
- University Hospital, Bordeaux
Systemic Sclerosis, Scleroderma
Cardiac Safe Transplants for Systemic Sclerosis
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
- Trial name
- CAST (NCT03593902)
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Scleroderma, Mildly Elevated Pulmonary Pressures
Sildenafil for Early Pulmonary Vascular Disease in Scleroderma
This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective…
- Trial name
- SEPVADIS (NCT04797286)
- Testing
- Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD).
- Trial name
- BLISSc-ILD (NCT05878717)
- Testing
- Belimumab
- Where
- 134 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
CREST Syndrome, Peripheral Vascular Disease
Exparel as a Nerve Block for Severe Hand Pain
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Trial name
- NCT02374320
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jose Soberon, MD
Systemic Scleroderma
Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled.
- Trial name
- NCT07502105
- Testing
- Firsekibart injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital